Cytek Biosciences Inc
CTKB5.100USD
+0.030+0.59%
收盘 12/26, 16:00（美东）报价延迟15分钟
652.11M总市值
亏损市盈率 TTM
关于 Cytek Biosciences Inc 公司
Cytek Biosciences, Inc. is a cell analysis solutions company. The Company is advancing the cell analysis tools by delivering high-resolution, high-content, and high-sensitivity cell analysis utilizing its patented Full Spectrum Profiling (FSP) technology. Its platform includes its core FSP instruments, the Cytek Aurora and Northern Lights systems and the Cytek Aurora CS cell sorter; the Cytek Orion reagent cocktail preparation system; the Enhanced Small Particle (ESP) detection technology; the flow cytometer and imaging products under the Amnis and Guava brands, and reagents, software and service to provide a comprehensive and integrated suite of solutions for its customers. Its Cytek Aurora and Northern Lights systems are used in the study of infectious diseases, immunology, immunotherapy, immuno-oncology, oncology, and drug discovery. The Cytek Orion reagent cocktail preparation system enables researchers to fully automate the preparation of antibody cocktails for flow cytometry.
Cytek Biosciences Inc简介
公司代码CTKB
公司名称Cytek Biosciences Inc
上市日期Jul 23, 2021
CEOJiang (Wenbin)
员工数量648
证券类型Ordinary Share
年结日Jul 23
公司地址47215 Lakeview Boulevard
城市FREMONT
上市交易所NASDAQ OMX - NASDAQ BASIC
国家United States of America
邮编94538
电话18779229835
网址https://cytekbio.com
公司代码CTKB
上市日期Jul 23, 2021
CEOJiang (Wenbin)
Cytek Biosciences Inc公司高管
名称
名称/职务
职务
持股
持股变动
Dr. Ming Yan, Ph.D.
Dr. Ming Yan, Ph.D.
Co-Founder, Chief Technology Officer, Director
Co-Founder, Chief Technology Officer, Director
6.07M
+0.26%
Dr. Wenbin Jiang, Ph.D.
Dr. Wenbin Jiang, Ph.D.
Chairman of the Board, President, Chief Executive Officer, Co-Founder
Chairman of the Board, President, Chief Executive Officer, Co-Founder
5.36M
+0.79%
Ms. Valerie Barnett, J.D.
Ms. Valerie Barnett, J.D.
Chief Legal Officer and Corporate Secretary
Chief Legal Officer and Corporate Secretary
115.64K
+16.63%
Dr. Philippe Busque, Ph.D.
Dr. Philippe Busque, Ph.D.
Senior Vice President, Global Sales and Services
Senior Vice President, Global Sales and Services
18.92K
+18.83%
Ms. Deborah J. Neff
Ms. Deborah J. Neff
Lead Independent Director
Lead Independent Director
15.71K
--
Dr. Vera Imper, Ph.D.
Dr. Vera Imper, Ph.D.
Independent Director
Independent Director
15.71K
--
Mr. Michael Holder
Mr. Michael Holder
Independent Director
Independent Director
12.36K
+21.43%
Mr. William (Bill) Mccombe
Mr. William (Bill) Mccombe
Chief Financial Officer
Chief Financial Officer
--
--
Mr. Jack T. Ball, Jr.
Mr. Jack T. Ball, Jr.
Independent Director
Independent Director
--
--
名称
名称/职务
职务
持股
持股变动
Dr. Ming Yan, Ph.D.
Dr. Ming Yan, Ph.D.
Co-Founder, Chief Technology Officer, Director
Co-Founder, Chief Technology Officer, Director
6.07M
+0.26%
Dr. Wenbin Jiang, Ph.D.
Dr. Wenbin Jiang, Ph.D.
Chairman of the Board, President, Chief Executive Officer, Co-Founder
Chairman of the Board, President, Chief Executive Officer, Co-Founder
5.36M
+0.79%
Ms. Valerie Barnett, J.D.
Ms. Valerie Barnett, J.D.
Chief Legal Officer and Corporate Secretary
Chief Legal Officer and Corporate Secretary
115.64K
+16.63%
Dr. Philippe Busque, Ph.D.
Dr. Philippe Busque, Ph.D.
Senior Vice President, Global Sales and Services
Senior Vice President, Global Sales and Services
18.92K
+18.83%
Ms. Deborah J. Neff
Ms. Deborah J. Neff
Lead Independent Director
Lead Independent Director
15.71K
--
Dr. Vera Imper, Ph.D.
Dr. Vera Imper, Ph.D.
Independent Director
Independent Director
15.71K
--
收入明细
单位: USD更新时间: 10月6日 周一
单位: USD更新时间: 10月6日 周一
FY2025Q2
FY2025Q1
FY2024
FY2024Q4
FY2024Q3
FY2024Q2
FY2024Q1
FY2023
FY2023Q4
FY2023Q3
FY2023Q2
FY2023Q1
FY2022
FY2022Q4
FY2022Q3
FY2022Q2
FY2022Q1
FY2021
FY2020
FY2019
业务USD
名称
营收
占比
Biotechnology, pharmaceutical, distributor and CRO
23.85M
52.30%
Academia and government
21.75M
47.70%
地区USD
名称
营收
占比
United States
23.89M
52.40%
EMEA
12.31M
26.99%
APAC
7.87M
17.25%
Other
1.53M
3.36%
业务
地区
业务USD
名称
营收
占比
Biotechnology, pharmaceutical, distributor and CRO
23.85M
52.30%
Academia and government
21.75M
47.70%
股东统计
更新时间: 11月16日 周日
更新时间: 11月16日 周日
持股股东
股东类型
持股股东
持股股东
占比
BlackRock Institutional Trust Company, N.A.
11.89%
Topline Capital Management, LLC
5.43%
The Vanguard Group, Inc.
5.42%
HHLR Advisors, Ltd.
5.21%
Yan (Ming)
4.75%
其他
67.30%
持股股东
持股股东
占比
BlackRock Institutional Trust Company, N.A.
11.89%
Topline Capital Management, LLC
5.43%
The Vanguard Group, Inc.
5.42%
HHLR Advisors, Ltd.
5.21%
Yan (Ming)
4.75%
其他
67.30%
股东类型
持股股东
占比
Investment Advisor
28.05%
Investment Advisor/Hedge Fund
22.30%
Hedge Fund
9.95%
Individual Investor
9.31%
Research Firm
1.43%
Pension Fund
1.21%
Bank and Trust
0.17%
Family Office
0.12%
Venture Capital
0.06%
其他
27.39%
机构持股
更新时间: 12月8日 周一
更新时间: 12月8日 周一
报告期
机构数
持股数
持股占比
持股变动
2025Q4
319
80.93M
70.83%
-2.20K
2025Q3
325
80.93M
70.98%
+589.69K
2025Q2
322
80.49M
71.67%
+1.88M
2025Q1
319
78.68M
72.45%
-13.77M
2024Q4
315
78.50M
69.87%
+2.46M
2024Q3
291
75.89M
70.06%
-1.14M
2024Q2
277
76.97M
68.86%
-4.44M
2024Q1
273
87.08M
76.11%
-12.82M
2023Q4
268
85.37M
77.21%
+1.48M
2023Q3
258
83.84M
73.24%
+597.32K
查看更多
股东持股明细
名称
持股数
占比
持股变动
变动比例
公告日期
BlackRock Institutional Trust Company, N.A.
15.38M
12.09%
-1.12M
-6.80%
Jun 30, 2025
Topline Capital Management, LLC
5.23M
4.11%
+3.76M
+255.68%
Jun 30, 2025
The Vanguard Group, Inc.
7.74M
6.08%
-1.86M
-19.35%
Jun 30, 2025
HHLR Advisors, Ltd.
6.66M
5.23%
--
--
Jun 30, 2025
Yan (Ming)
6.06M
4.76%
+15.29K
+0.25%
Aug 18, 2025
Jiang (Wenbin)
5.31M
4.18%
+52.68K
+1.00%
Aug 18, 2025
Brown Capital Management, LLC
7.11M
5.59%
-353.97K
-4.74%
Jun 30, 2025
State Street Investment Management (US)
4.17M
3.28%
-208.41K
-4.76%
Jun 30, 2025
Millennium Management LLC
924.77K
0.73%
+429.33K
+86.66%
Jun 30, 2025
Dimensional Fund Advisors, L.P.
3.45M
2.72%
+601.00K
+21.06%
Jun 30, 2025
查看更多
持股ETF
更新时间: 12月6日 周六
更新时间: 12月6日 周六
机构名称
占比
Invesco S&P SmallCap Health Care ETF
0.26%
Royce Quant Small-Cap Quality Value ETF
0.22%
iShares S&P Small-Cap 600 Value ETF
0.09%
Goldman Sachs ActiveBeta US Small Cap Equity ETF
0.07%
State Street SPDR S&P 600 Small Cap Value ETF
0.06%
Avantis US Small Cap Equity ETF
0.05%
Invesco S&P SmallCap 600 QVM Multi-factor ETF
0.05%
Fidelity Enhanced Small Cap ETF
0.05%
Principal U.S. Small-Cap ETF
0.05%
WisdomTree US SmallCap Fund
0.04%
查看更多
Invesco S&P SmallCap Health Care ETF
占比0.26%
Royce Quant Small-Cap Quality Value ETF
占比0.22%
iShares S&P Small-Cap 600 Value ETF
占比0.09%
Goldman Sachs ActiveBeta US Small Cap Equity ETF
占比0.07%
State Street SPDR S&P 600 Small Cap Value ETF
占比0.06%
Avantis US Small Cap Equity ETF
占比0.05%
Invesco S&P SmallCap 600 QVM Multi-factor ETF
占比0.05%
Fidelity Enhanced Small Cap ETF
占比0.05%
Principal U.S. Small-Cap ETF
占比0.05%
WisdomTree US SmallCap Fund
占比0.04%
分红派息
近5年累计派现
0.00
美元
公告日期
分红计划
股权登记日
现金发放日
除权除息日
暂无数据
拆合股
公告日期
类型
比率
暂无数据
公告日期
类型
比率
暂无数据
常见问题
Cytek Biosciences Inc的前五大股东是谁？
Cytek Biosciences Inc 的前五大股东如下：
BlackRock Institutional Trust Company, N.A.持有股份：15.38M，占总股份比例：12.09%。
Topline Capital Management, LLC持有股份：5.23M，占总股份比例：4.11%。
The Vanguard Group, Inc.持有股份：7.74M，占总股份比例：6.08%。
HHLR Advisors, Ltd.持有股份：6.66M，占总股份比例：5.23%。
Yan (Ming)持有股份：6.06M，占总股份比例：4.76%。
BlackRock Institutional Trust Company, N.A.持有股份：15.38M，占总股份比例：12.09%。
Topline Capital Management, LLC持有股份：5.23M，占总股份比例：4.11%。
The Vanguard Group, Inc.持有股份：7.74M，占总股份比例：6.08%。
HHLR Advisors, Ltd.持有股份：6.66M，占总股份比例：5.23%。
Yan (Ming)持有股份：6.06M，占总股份比例：4.76%。
Cytek Biosciences Inc的前三大股东类型是什么？
Cytek Biosciences Inc 的前三大股东类型分别是：
BlackRock Institutional Trust Company, N.A.
Topline Capital Management, LLC
The Vanguard Group, Inc.
BlackRock Institutional Trust Company, N.A.
Topline Capital Management, LLC
The Vanguard Group, Inc.
有多少机构持有Cytek Biosciences Inc(CTKB)的股份？
截至2025Q4，共有319家机构持有Cytek Biosciences Inc的股份，合计持有的股份价值约为80.93M，占公司总股份的70.83%。与2025Q3相比，机构持股有所增加，增幅为-0.14%。
哪个业务部门对Cytek Biosciences Inc的收入贡献最大？
在FY2025Q2，Biotechnology, pharmaceutical, distributor and CRO业务部门对Cytek Biosciences Inc的收入贡献最大，创收23.85M，占总收入的52.30%。
